What the African femtech market is really telling us
A mismatch between the products being built, the evidence behind them and where investment is flowing
In this guest post for FutureFemHealth, Dr Ayomide Owodunni shares her insights on the African femtech market and the opportunities for the ecosytem.
Africa isn’t a FemTech frontier waiting to be discovered. It is a FemTech market, one of the most commercially significant women’s health opportunities the global industry has yet to fully recognize.
More than 580 million women live on the continent, and they’re navigating health systems that were rarely built with them in mind, with digital health adoption rising fast. FemTech in the Middle East and Africa is projected to grow at over 15% annually between 2025 and 2030, yet the region still accounts for a small share of global FemTech revenue. The gap is not demand but rather a mismatch between the products being built, the evidence behind them, and where investment is actually flowing.
Many of these gaps surfaced at the inaugural Better Woman Health Conference, which brought together clinicians, investors, founders, and health-conscious women for an honest conversation about where the ecosystem is falling short.
Building on borrowed data
A lot of the clinical research shaping women’s health innovation today was done outside African populations. That means many products coming into African markets are built on assumptions about biology, health behaviour, and how people access care that simply don’t hold up locally.
That’s both a problem and an opening. In healthcare, evidence is infrastructure. Founders willing to generate credible local data now won’t just build better products; they’ll build the groundwork the whole ecosystem needs, setting the standards everyone else gets measured against.
The clinician trust gap
In most African health systems people trust their doctors. But a lot of digital health products are built for patients first, with clinicians brought in as an afterthought.
The companies gaining traction are those investing early in clinical validation, setting clear safety boundaries, and showing measurable outcomes before they try to scale. When clinicians trust a product, they become its biggest advocates. Without that trust, scale becomes difficult regardless of how many users you have.
Due diligence now includes clinical safety questions at every stage. To help founders identify these gaps earlier, I developed the Clinical Credibility Safety Scorecard, a free assessment tool designed to evaluate clinical foundation and safety architecture.
The funding gap
African FemTech is getting investment, but it’s going to the same few areas. Companies like Kasha and Zoie Health show what’s possible: Kasha raised $21 million in a Series B, and Zoie Health secured a pre-seed extension to grow virtual women’s care in South Africa. These are real success stories. But sadly, they’re outliers.
Around 81% of funded African FemTech startups are focused on fertility. Meanwhile, menopause, pelvic health, and endometriosis are barely visible to investors even though millions of women are living with these conditions right now.
Where the opportunities lie
Menopause care. Millions of women go through menopause on the continent with almost no dedicated support. It’s culturally underdiscussed and commercially ignored, which means there’s real space for education tools, symptom management, and long-term care models.
Postpartum health. This might be the most glaring gap. Postpartum depression affects up to 25% of women in some African settings. Yet there’s almost no digital infrastructure to help identify or support it. After leaving the hospital, most women get no structured follow-up and no mental health screening at such a vulnerable point in their health journey.
Data-driven diagnostics. Conditions like PCOS and endometriosis are massively underdiagnosed across the continent. Tools built on African clinical data could completely reshape how these conditions are identified while generating proprietary evidence that has real long-term value.
These opportunities share a common theme: success will depend less on rapid user acquisition and more on clinical credibility and measurable outcomes.
A market already in motion
Women across Africa are already adopting digital health tools. The challenge isn’t getting people to engage; it’s making sure the products actually fit their clinical reality and are backed by solid evidence.
The next phase of African FemTech growth is unlikely to be defined by adapting solutions built elsewhere. It’ll come from companies built with local context from day one. Combining scientific grounding with commercial strategy.
Africa isn’t waiting. The founders and investors who move now won’t just capture a market; they’ll define it.
Dr Ayomide is a medical writer who helps FemTech brands create evidence-based content that builds trust with customers and credibility with investors. Visit Dr Ayomide’s website here.